MS and Demyelinating Disorders

Patient/guardian decision, adverse event, and physician decision were the 3 noted reasons for discontinuation with either ofatumumab or teriflunomide.

Leaders in neurology provide insight into first-line disease-modifying therapies for relapsing-remitting multiple sclerosis, such as interferon or glatiramer acetate, and glucocorticoids for acute events.

The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.

Richard shares his experience receiving his infusion therapy for treatment of multiple sclerosis.

An expert neurologist discusses treatment options for progressive multiple sclerosis.

Clyde E. Markowitz, MD, comments on the growing role of magnetic resonance imaging to help diagnose multiple sclerosis and highlights characteristics of lesions he looks at during a diagnostic evaluation.

Patricia K. Coyle, MD, highlights revisions to the McDonald diagnostic criteria for multiple sclerosis and emphasizes why health care professionals need to start referring to the criteria in a more standard fashion.

Here's what is coming soon to NeurologyLive.

Results from the ongoing clinical trial will help define clinical management guidelines for switching patients with relapsing MS on other disease-modifying therapies to siponimod.

Neurology News Network for the week ending April 17, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 16, 2021.

Kimberly Allen-Philbey, a PhD candidate at the Barts MS Center in London, discussed the advantages of using a personalized dosing schedule of off-label, subcutaneous cladribine.

Experts in progressive multiple sclerosis summarize the phase 2 SPRINT-MS trial and the rationale for treating patients with ibudilast.

A discussion of how experts treat nonactive multiple sclerosis in terms of trial results or symptom management and how decisions are based on patient age.

Findings suggest that the neuroprotective therapeutic response from rituximab in patients with relapsing-remitting multiple sclerosis may take up to 12 months.

The 2021 AAN Annual Meeting will be held virtually from April 17-22. Follow along with coverage from NeurologyLive, including expert interviews and session recaps.

The senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about further research his lab is conducting into MS mechanisms.

Jemima Akinsanya, DO, Neuroimmunology Clinical Fellow at the National Institutes of Health, discussed new studies of anakinra and tolebrutinib in MS.

The senior director of patient management, care, and rehabilitation research at the National MS Society discussed symptoms of progressive MS that need more attention and research.

Tanuja Chitnis, MD reviews the 2018 AAN guidelines on disease-modifying therapies and discusses goals of therapy when selecting first-line treatments and monitoring response in pediatric multiple sclerosis.

Experts in multiple sclerosis discuss the importance of a multidisciplinary approach for pediatric patients and emphasize the role of social workers, psychologists, and support groups for patients and families.  

The postdoctoral researcher at Columbia University discussed the use of the DISCO-MS survey and its potential for future research projects.

Ilena George, MD, of Massachusetts General Hospital, discussed a cohort of patients with early DMT prescription and low rates of clinical conversion.

Richard describes the journey of his diagnosis with multiple sclerosis.

Here's what is coming soon to NeurologyLive.